Hyperfine has announced the European launch of its next-generation Swoop system—an artificial intelligence (AI)-powered portable magnetic resonance imaging (MRI) system for the brain featuring the latest advancement in Optive AI software.
According to the company, this marks a significant milestone in the global expansion of its most advanced portable MRI technology, supporting international commercial growth and improving global access to high-quality brain imaging at the point of care.
Following CE mark and UKCA approvals, the next-generation Swoop system—also known as Model 2—is now commercially available across an initial wave of European markets.
“I’ve been involved with Hyperfine since the earliest days of portable MRI, and the relentless progress has been remarkable,” said Steve Williams (King’s College London, London, UK). “With the next-generation Swoop system, the improvement in image quality is transformative. Having spent my career exploring advanced brain imaging, I am impressed that low-field MRI can provide this level of diagnostic-quality images. For years, limited access to neuroimaging has delayed diagnosis and treatment for countless patients around the world. The Swoop system is uniquely positioned to address that gap, making MRI accessible when and where it is needed, even in remote locations, to support decision-making in a wider range of care settings across the lifespan.”
Hyperfine has also announced the inclusion of its next-generation Swoop system in the UniHA procurement listing—a “key milestone” enabling broader adoption across hospitals within the French public healthcare system. The initial inclusion of the Swoop system in this listing was in October 2025.
“We are proud to bring Hyperfine’s most advanced portable MRI technology to clinicians across Europe and the UK, delivering on an important milestone for our commercialisation strategy in 2026,” said Eric Willis, vice president of international at Hyperfine. “The next-generation system delivers significant improvements in image quality, workflow efficiency, and clinical capability. We have already seen these advancements accelerate use and adoption of the Swoop system throughout the USA. We look forward to working closely with our distribution partners to expand access to AI-powered portable MRI across Europe, providing critical neuroimaging that helps clinicians make more timely and more informed patient care decisions. By the end of the year, we plan to make the Model 2 Swoop system available through our distribution partners across all European markets where Hyperfine is represented.”
